• DOI:10.1016/J.PHRS.2007.09.015
Corpus ID: 19675627

Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity.

@article{Garbin2007NebivololRA,
  title={Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity.},
  author={U. Garbin and A. Pasini and C. Stranieri and S. Manfro and V. Boccioletti and L. Cominacini},
  journal={Pharmacological research},
  year={2007},
  volume={56 6},
  pages={
          515-21
        }
}

U. Garbin, A. Pasini, +3 authors L. Cominacini

Published 2007

Chemistry, Medicine

Pharmacological research

Asymmetric dimethylarginine (ADMA) has been reported to affect the synthesis of nitric oxide (NO) in endothelial cells by inhibiting endothelial NO synthase (eNOS) activity and to cause endothelial dysfunction in humans. This study was conducted in human umbilical vein endothelial cells (HUVECs) to evaluate the effect of nebivolol, a selective beta1-adrenergic receptor antagonist, on ADMA concentration and on dimethylarginine dimethylaminohydrolase (DDAH2), the enzyme that regulates ADMA… CONTINUE READING

View on PubMed

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed